Amgen

We are all different, yet we have this in common: our mission to serve patients. This sense of shared purpose is key to our becoming one of the world’s leading biotechnology companies. It guides us as we continue to launch new medicines and reach millions of patients worldwide.

We live the mission.

We win together.

We thrive on continual challenge.

Our team of 27,000+ scientists and professionals worldwide bring distinct perspectives and experiences to all we do. We leverage our global talent to achieve together—to research, manufacture and deliver ever-better products and greater depth to our mission.

At Amgen, there is a strong correlation between our high level of diversity and performance. Because addressing issues with a wider range of perspectives and approaches leads to more creative problem-solving. Together, we’re transforming the promise of science and biotechnology into therapies that have the power to restore health.

Connect with us to explore how you can Win, Live, and Thrive at Amgen.

AWARDS

Corporate Headquarters
One Amgen Center Drive
Thousand Oaks, CA 91320

Tel: 805-447-1000

Visit website

Email Us

LIVE. WIN. THRIVE.

We know an idea—any idea—can blossom into a lifesaving treatment. That’s why we dare to ask the questions most people won’t. Join us in pushing biotechnology.

Join Us

Employee Testimonials

“Amgen fosters a culture of innovation, with a science-based risk approach, centered in the benefit of our patients and powered by the diversity of our staff.”

Jorge D.
Porcess Scientific Director
Juncos, PR
“Cultivate your curiosity and continue to learn at Amgen — grow daily and explore career opportunities that align with your competencies and motivation”

Fernando F.
Executive Director Plant Manager
Rhode Island, US
“Working at Amgen, as Specialist Quality Control gives me the opportunity to work with Amgen products in benefit of the patients. Using my knowledge in science and share my diversity with my peers, is the best experience I have as part of the Amgen family.”

Niria R.
Specialist Quality Control
Juncos, PR

Diversity and Inclusion
Benefits
Community Investment
Awards and Accolades

Serving patients across the globe requires a global team. We continue building a diverse workforce that reflects the needs of those they serve, bringing with them innovative ideas that can push biotechnology forward.

Learn More

We offer more than benefits. Our Total Rewards Program secures the long-term financial, physical and overall well-being of you and your family. Among leading biotechnology and pharmaceutical leaders, we stand among the very best.

Learn More

Through Amgen Volunteers, you can dedicate eight hours to participating organizations of your choice. This along with matching employee donations to charities and our diverse corporate giving initiatives are just some ways you can make meaningful contributions as a global citizen

Learn More

Amgen is proud of the achievements we have realized as a mission-driven team—particularly the accolades we have earned as an employer. You can find our teams named in respected lists including Forbes, Fast Company and more.

Learn More

NEWS

Aubrey Adams, AbbVie's U.S. Area Head for Therape

Drug Development

Following its North Star, AbbVie is Taking the Reigns in Migraine Treatment

Since its $63 billion acquisition of Allergan in 2019, AbbVie has become one of the leading companies developing therapies for migraine.

April 29, 2022

6 min read

Alex Keown

Pictured: Amgen sign/courtesy Al Seib/Los Angeles

Business

Amgen Battles IRS Over Billions in “Wholly Unwarranted” Tax Penalties

Amgen held its earnings conference call on Wednesday for Q1 of 2022. Most notably, the company provided updates on its ongoing litigation with the Internal Revenue Service.

April 27, 2022

2 min read

Rosemary Scott

Business

Molecular Partners Collab Falls Victim to Amgen Strategic Pipeline Review

All development and commercialization rights for MP0310, a clinical stage immunomodulator intended to treat solid tumors, will be reverted to Molecular Partners.

April 27, 2022

2 min read

Jazmine Colatriano

Business

AstraZeneca and Daiichi Sankyo Score Priority Review in NSCLC

AstraZeneca and Daiichi Sankyo reported that their supplemental Biologics License Application (sBLA) for Enhertu was granted Priority Review by the U.S. Food and Drug Administration.

April 19, 2022

3 min read

Mark Terry

Drug Development

Clinical Catch-Up: AACR, AAN and COVID-19

It was a very busy week for clinical trial news, with much of it coming out of the American Association of Cancer Research Annual Meeting. Read on for details.

April 15, 2022

12 min read

Mark Terry

A Novartis building under a blue sky/courtesy of C

Drug Development

Novartis Highlights Early Data from Potential Lumakras Competitor at AACR

Although the data was preliminary from a Phase Ib trial, investors are already speculating that the drug - when and if it makes it to regulators - could compete with Amgen’s Lumakras (sotorasib).

April 12, 2022

3 min read

Mark Terry

AACR: The Weekend Winners - Amgen, Bicycle and BioNTech

Data presented at the AACR Annual Meeting over the weekend will likely lead to continued stock jumps for Amgen, Bicycle Therapeutics and BioNTech.

April 11, 2022

2 min read

Jazmine Colatriano, M.S.

Policy

US Congress Introduces Bills to Strengthen Pharma Competition, Promote Innovation

The new bills result from a three-year investigation that honed in on anti-competitive efforts that have prevented generic drugs and biosimilars from entering the market.

April 8, 2022

3 min read

Alex Keown

Drug Development

More Unique Therapeutic Possibilities Posed by Rare Human Genes

The discovery of a unique, inheritable resistance to Ebola infection has inspired the development of therapeutics that may not only be effective against Ebola but against COVID-19, as well.

March 11, 2022

5 min read

Kaylei Whalen

JOBS